LEXX Stock Analysis: Buy, Sell, or Hold?
LEXX - Lexaria Bioscience Corp. Common Stock
$0.56
-0.03 (-5.30%)
▼
5d:
-7.28%
30d:
-45.55%
90d:
-13.68%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: Apr 13, 2026
0d
Get Alerted When LEXX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called LEXX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LEXX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LEXX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LEXX is currently trading at $0.56, which is considered oversold relative to its 30-day fair value range of $0.63 to $0.97.
Technical Outlook: Technically, LEXX is in a uptrend. The price is currently testing key support at $0.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: LEXX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.75 (+533.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LEXX is in a uptrend. The price is currently testing key support at $0.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: LEXX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.75 (+533.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.63 -
$0.97
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 533.2% below Wall St target ($3.75)
- CAUTION: 5-day price weakness (-7.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.63 -
$0.97
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.55
Resistance Level
$0.73
Current Trend
Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.91
Wall Street Target
$3.75
(+533.2%)
Revenue Growth (YoY)
-88.5%
Share & Embed Analysis
Last updated: May 18, 2026 2:05 PM ET
Data refreshes hourly during market hours. Next update: 3:05 PM
Data refreshes hourly during market hours. Next update: 3:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LEXX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 45 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 50 HOLD |
